Epidemiology Resume Crossover: From MPH-Academic to Industry-Epidemiologist to Public-Health-Tech — The Three Pathways Most Epi Resumes Conflate

Epidemiology Is Three Different Career Pathways, Not One

Generic resume coaches treat "epidemiologist" as a single category. Pharma hiring managers, academic search committees, and public-health-tech recruiters treat academic epidemiology, industry epidemiology (pharma RWE, biotech, payer-analytics), and public-health-tech epidemiology as three distinct hires with three different methodology emphases, three different credential expectations, and three different salary bands.

The mis-targeted epi resume — methodology-heavy in the wrong dimension, credential-mismatched for the destination role — is the single most common failure mode. An academic epi resume that emphasizes infectious-disease-outbreak-modeling reads weak for a pharma RWE role that screens for claims-database fluency + causal-inference framing. A pharma-RWE-pivot resume that surfaces only academic publications reads junior for the industry-Senior-Epidemiologist tier that wants P&L-adjacent regulatory submissions experience.

This post is the deep-dive on the epi resume — pathway by pathway, credential by credential, plus the named-methodology resume signals that the generic resume coaches miss, plus the pivot pathways for academic epidemiologists moving into industry and industry epidemiologists moving into public-health-tech. It's the narrow companion to the public health resume non-academic post, which covered the broad public-health-employer landscape; iter-75 (this post) goes deep on the epidemiology vertical specifically. For The Pharm's career-stage architecture, see the mid-career growth track and the career-pivot growth track.

The Three Epidemiology Pathways — Pathway Distinction Matrix

Three adjacent but materially-different career trajectories:

Academic Epidemiology: faculty positions at schools of public health (Johns Hopkins, Harvard Chan, Columbia Mailman, UNC Gillings, Michigan, Berkeley, etc.) + research-faculty positions at academic medical centers. KPI portfolio is NIH-grant-funded research, peer-reviewed publications, doctoral-student advising, and methodology contribution. Standard pathway: MPH or MSPH → PhD-Epi → postdoc → assistant professor (years 6-8 post-PhD) → tenured associate professor (years 12-16). Salary range $90-$160K assistant, $130-$220K associate, $180-$300K full professor.

Industry Epidemiology: pharma + biotech + medical-device + commercial-payer + diagnostics hire epidemiologists for real-world-evidence (RWE) generation, post-marketing safety surveillance, comparative-effectiveness research, market-access health-economics-and-outcomes-research (HEOR), and regulatory submissions. KPI portfolio is regulatory-submission-quality (FDA, EMA, PMDA), publication-strategy for label-expansion, payer-evidence-packets, and competitive-intelligence work. Standard pathway: MS-Epi or PhD-Epi → 1-3 years junior epidemiologist → Senior Epidemiologist (years 5-8) → Director, RWE (years 10-15) → VP, Epidemiology (years 15-20). Salary range $90-$130K junior, $130-$190K senior, $180-$280K director, $250-$450K+ VP.

Public-Health-Tech Epidemiology: digital-health platforms (Flatiron Health, OptumLabs, Komodo Health, Truveta, Tempus, Verana Health, etc.), EHR-vendor-analytics teams (Epic Cosmos, Cerner-now-Oracle Health Health Data Intelligence), claims-clearing-houses (IQVIA, Symphony Health), and payer-tech (HealthEdge, Cotiviti, ClarisHealth) hire epidemiologists as senior data scientists, clinical-product managers, RWE solution architects, and analytics directors. KPI portfolio is product-ready analytics modules, customer-facing study design, methodology innovation at platform-scale (datasets ranging 10M to 300M+ patient lives), and publication output that drives platform credibility. Salary range $130-$200K junior, $190-$280K senior, $260-$420K director, $380-$650K+ VP (often with equity).

Resume framing implication: pathway-target is THE first decision. An academic-targeted resume leads with publications + grant funding + teaching impact; an industry-targeted resume leads with regulatory-submission contributions + database fluency + business-impact metrics; a public-health-tech-targeted resume leads with platform-scale dataset experience + Python/R production-code authorship + customer-facing-deliverable history. The pathway choice drives every other resume decision.

Per BLS Epidemiologists OOH, the field projects 27% growth through 2032 — among the fastest in any healthcare-adjacent role. The unstated detail: 27% growth is heavily weighted toward industry + public-health-tech, NOT academic. Academic-pathway-supply (PhDs minted annually by CEPH-accredited schools) outpaces academic-pathway-demand significantly; the academic-to-industry pivot is the single most common epi career transition.

Credential Ladder — MPH vs MS-Epi vs PhD-Epi vs CPH

Epidemiology credentials don't form a single linear ladder. They form a matrix where the right credential depends on the target pathway:

MPH (Master of Public Health) — issued by CEPH-accredited schools of public health. 2-year master's, broad public-health curriculum with concentration in epidemiology, biostatistics, environmental-health, or health-policy. The MPH-with-epi-concentration is the canonical entry credential for state-DOH, CDC contractor, and many public-health-non-profit positions. Industry hires MPH-with-epi-concentration candidates for junior epi roles but increasingly screens for MS-Epi or PhD-Epi at senior tiers.

MS-Epi (Master of Science in Epidemiology) — methodology-heavier than the MPH. 2-year master's with deeper biostatistics, study-design, and causal-inference coursework. Increasingly the credential industry pharma + biotech screens for at the Senior Epidemiologist tier. The MS-Epi vs MPH-with-Epi-concentration question is a real distinction: for industry-pharma career arcs, the MS-Epi typically opens more doors faster.

PhD-Epi — research-degree, 4-6 years post-master's. Required for academic-faculty pathways. Increasingly held by industry Senior Epidemiologists at major pharma (Pfizer, AstraZeneca, Bristol Myers Squibb, Roche, Novartis, Merck, GSK, AbbVie). For public-health-tech, the PhD is a strong-but-not-required differentiator at the senior tier. The post-PhD-postdoc decision (do an academic postdoc vs go-directly-industry) is itself a career-defining choice.

CPH (Certified in Public Health) — issued by NBPHE (National Board of Public Health Examiners). Practice-based credential for MPH-and-above public-health professionals. Functions as a professional-recognition marker more than a hiring gate; required for CHES-CPH dual-credentialed positions at some non-profits and state DOHs. Easier to maintain than to earn — the value is in showing public-health-professional-identity discipline, not in unlocking specific roles.

Optional specialty credentials: SER (Society for Epidemiologic Research) membership + the SER Annual Meeting attendance/abstract record functions as a professional-network signal. SAS-Certified-Advanced-Programmer or AWS-Certified-Data-Analytics functions as a technical-skills marker for industry + public-health-tech pivots.

Resume framing: list the terminal degree (MS-Epi or PhD-Epi) prominently in the header, then list specialty credentials (CPH if held) and technical-skills credentials (SAS, AWS) below. For academic-targeted resumes: surface NIH F-32 / F-31 / K-99 grant history if applicable; for industry-targeted resumes: surface regulatory-submission contributions; for public-health-tech-targeted resumes: surface dataset-scale (named: "5M-life claims database" or "12M-patient EHR dataset") and publications-driven-by-platform-data.

Setting-Specific Resume Framing

Same credential, target-different setting → meaningfully different resume:

Academic Faculty / Research Faculty: surface NIH-grant-funded-research history (named grants — F-32, K-99/R00, R03, R21, R01 with PI vs co-PI distinction), peer-reviewed publication count + h-index, named-methodology contributions, doctoral-student-advising history if applicable, named-conference-presentation history (SER, IDWeek, AHA EPI-Lifestyle, AcademyHealth ARM). Academic search committees read for "this candidate will be tenure-track-promotable in 6 years."

CDC Contractor (CSTE Applied Epidemiology Fellowship, EIS alum, CDC Foundation, ORISE): surface field-epi-investigation history (named outbreaks, named-pathogen experience, named-MMWR-publication contributions), state-DOH-collaboration patterns, named-data-sources (NNDSS, NEDSS, NHANES, BRFSS), and any prior CSTE conference attendance. CDC contractor search committees read for "can this epi run a field investigation in 72 hours with limited data and produce a defensible report."

State Department of Health Epidemiology: surface state-DOH-specific-program fluency (Title V Maternal-Child Health, ELC cooperative agreement work, BRFSS surveillance, cancer-registry coordination), named state-data-system experience (state-specific surveillance platforms, named MCO-payer-data linkages), and any prior CSTE-NNDSS work. State DOH search committees read for "can this epi run surveillance + outbreak response + report to legislators on the same week."

Pharma RWE (Real-World Evidence): surface claims-database fluency (named: IQVIA PharMetrics Plus, Optum Clinformatics, Marketscan, TriNetX, IBM Health Insights), EHR-database fluency (named: Flatiron, Optum EHR, Cerner HealtheDataLab), regulatory-submission contributions (named FDA divisions worked with — CDER, CBER, OND, OBE), publication-strategy contributions (label-expansion publications, payer-evidence-packet publications), and any prior PDUFA-deadline-driven work. Pharma hiring managers read for "can this epi own a section of an FDA submission and defend it in an Advisory Committee meeting."

Keyerrá personally reads every submission and rewrites your resume using the CAR + Callout method — healthcare-fluent, ATS-ready, STAR-interview-ready.

Biotech Early-Phase Epidemiology: surface adaptive-trial-design fluency, rare-disease-natural-history-study design, master-protocol experience, surrogate-endpoint-validation work, and any prior real-time-clinical-trial-collaboration with statistical-programming and clinical operations. Biotech hiring committees read for "can this epi design the natural-history study that frames the Phase II protocol AND defend it in front of the FDA team in pre-IND."

Payer Analytics (Anthem-now-Elevance / United / Humana / Cigna / BCBS plans): surface medical-management-rule-development experience, value-based-contract-design contribution, total-cost-of-care modeling fluency, named-MCO-platform fluency (named: Cotiviti, HealthEdge, ClarisHealth), CMS-VBP-program-design work, and any prior actuarial-collaboration history. Payer hiring committees read for "can this epi build the economic case for a new prior-authorization rule and defend it to the medical-policy committee."

Public-Health-Tech Platforms (Flatiron, OptumLabs, Komodo, Truveta, Tempus, Verana, Epic Cosmos): surface platform-scale-dataset experience explicitly (named patient-life-count, named cohort-construction projects, named customer-deliverables), Python + R + SQL production-code-authorship history, named-methodology contributions to platform tooling, and any prior customer-facing study design or sales-enablement work. Public-health-tech search committees read for "can this epi own a customer's RWE study from intake-call to deliverable in 6-8 weeks at platform scale."

Named-Methodology Resume Signals — The Under-Surfaced Differentiation

Generic resume coaches don't surface specific methodologies. Hiring committees screen heavily for them. Methodology signals that meaningfully differentiate epi resumes:

Causal-inference framing: name the methods. Directed Acyclic Graphs (DAGs) for confounder-identification + selection-bias diagnosis. Inverse probability of treatment weighting (IPTW) for confounding-adjustment. Target Trial Emulation framework (Hernán + Robins) for observational-study design. Marginal Structural Models for time-varying confounding. Instrumental Variable analysis for endogeneity-correction. G-computation for counterfactual estimation. Listing these by name signals "this candidate has done the methodology coursework and applied it" much more strongly than the generic "performed regression analysis."

Study-design fluency: cohort + case-control + nested case-control + case-cohort + cross-sectional + ecological + Mendelian-randomization. Surface specific design-types the candidate has used, with population-size + follow-up-duration if applicable.

Statistical-programming fluency: name the platforms. R (specific packages: survival, lme4, mgcv, ipw, tableone, mice, ggplot2). SAS (specific procedures: PROC PHREG, PROC LIFETEST, PROC GLIMMIX, PROC NLMIXED). Python (specific libraries: pandas, scikit-learn, lifelines, statsmodels, PyMC). Stata (specific commands: stcox, mi impute, teffects). Listing platforms generically reads weaker than listing specific procedures/packages applied to specific projects.

Database-platform fluency: for industry + public-health-tech pivots, name the database platforms worked with. Claims: IQVIA PharMetrics Plus / Optum Clinformatics DataMart / Marketscan Treatment Pathways / Symphony Health PatientSource. EHR: Flatiron / Optum EHR / Cerner HealtheDataLab / Veradigm / TriNetX. Public: NNDSS, NHANES, BRFSS, NHIS, SEER. The platform-fluency signal moves resumes from "generic epi" to "ready to bill on day 1."

Resume framing: methodology + statistical-programming + database-platform fluency should each occupy a labeled section in the resume — not buried in skills list. The dedicated section signals "this candidate has methodology depth, not just methodology vocabulary."

Pivot Pathways — Academic-to-Industry, Industry-to-Public-Health-Tech, Public-Health-to-Policy

The three most-common epi pivot pathways:

Academic-to-Industry (the #1 epi pivot): PhD-Epi or postdoc → pharma RWE Senior Epidemiologist or biotech early-phase epi. Salary jump typically $90-$130K postdoc → $130-$190K Senior Epidemiologist. Resume framing for this pivot: lead with methodology + dataset-scale + regulatory-relevance work (downplay teaching impact and academic-conference presentations unless they're FDA-Advisory-Committee-relevant). The framework covered in the why-this-pivot interview story post applies directly — frame the pivot as expansion of methodology impact into regulatory + commercial decision-making rather than abandonment of research rigor.

Industry-to-Public-Health-Tech: pharma-RWE Senior Epidemiologist → public-health-tech Principal Epidemiologist or Director-of-Analytics. Salary jump typically $180-$260K pharma director → $260-$420K + equity public-health-tech director. Resume framing: lead with platform-scale work, customer-facing deliverable history, and methodology-tooling contributions (e.g., "co-authored R package adopted by Flatiron customer-engineering team for cohort construction"). The bedside-to-tech pivot framework covered in the clinical informatics nurse resume post applies analogously — surface the bridging work, name the platform exposure, and frame the pivot as expansion of epidemiological influence into product rather than abandonment of methodology.

Public-Health-to-Policy Advocacy: state-DOH epi or CDC contractor → think-tank policy researcher (Brookings, RAND, Mathematica, Urban Institute, Manatt Health) or federal-agency policy analyst (CMMI, HHS-OIG, AHRQ, HRSA). Salary range $130-$220K depending on level + institution. Resume framing: surface policy-relevant publications, named-legislative-testimony-or-briefing history if applicable, surveillance-program-leadership impact, and any prior federal-agency-collaboration experience. The Epic-analyst-pivot framework covered in the Epic analyst resume post maps analogously for the bridging-work pattern (CAHIMS coursework + HIMSS attendance → think-tank fellowships + Health Affairs publication + state-legislator briefings).

FAQs

Q: I'm a PhD-Epi in postdoc considering academic vs industry. How do I decide? The honest deciding factor: how much weight do you put on tenure-track autonomy vs faster compensation growth + structured-deliverable work? Academic offers methodology autonomy + the legacy-impact-via-PhD-students arc, with a long tenure-track ramp and salary plateau in the $130-$220K range. Industry offers faster comp growth (Senior Epidemiologist at year 3-5 in pharma typically out-earns assistant professor at year 6-8 academic by $40-$80K), structured deliverables (you'll know what counts as "good work" much more clearly), and lower tolerance for methodology improvisation. The pivot is reversible toward industry-from-academic; the reverse direction is much harder. If you're 50/50 today, the asymmetric-reversibility favors trying industry first.

Q: MS-Epi or MPH-with-Epi-concentration — which is the better master's for an industry-RWE career arc? MS-Epi for industry-pharma-RWE. The biostatistics + study-design + causal-inference coursework is meaningfully deeper at the MS-Epi level, and pharma hiring managers screen for it. MPH-with-Epi-concentration is broader (includes health-policy, environmental-health, social-behavioral exposure) and is the better choice for state-DOH + CDC + public-health-nonprofit arcs. For public-health-tech: substantively equivalent — the master's matters less than the technical-skills + dataset-scale exposure.

Q: How early should I pursue CPH — and is it worth it for industry-pharma roles? CPH is largely irrelevant for industry-pharma + biotech hiring. It matters for state-DOH + non-profit + some CDC-contractor positions, and for personal-professional-identity reasons. For industry pivots, allocate continuing-education investment to SAS-certified, AWS-certified, or specific-methodology training (causal-inference workshops, R-bootcamps, machine-learning-for-epidemiology) over CPH. For public-health-track candidates: pursue CPH if you're long-term-committed to state-DOH or public-health-non-profit work; skip if you're industry-bound.

Q: I'm a state-DOH epidemiologist (year 4) pivoting to pharma RWE. What's the realistic resume gap, and how do I close it? Three real gaps + concrete closures: (1) Claims-database fluency — most state DOH work uses surveillance + cohort data, not claims. Closure: pursue a part-time RWE contract, take an academic adjunct project that uses Marketscan/Optum/IQVIA, or attend an ISPOR conference and explicitly network into "shadow" claims work. (2) Regulatory-submission contributions — state DOH doesn't run FDA submissions. Closure: surface any prior CDC-MMWR-publication work as regulatory-adjacent rigor; volunteer for any state-DOH-to-FDA collaboration (rare but possible); or accept that the first industry role will be a junior epi tier ($110-$140K) with the goal of moving to Senior in 18-24 months. (3) Business-impact framing — state DOH measures success in surveillance-completeness and outbreak-response timeliness, NOT in revenue + cost. Closure: re-frame existing accomplishments in cost-or-revenue language ("surveillance program redesign that reduced reporting-cycle from 14 days to 4 days, freeing $180K in epidemiologist-time annually").

Q: What's the realistic salary trajectory in industry-pharma RWE from junior to Director? Year 0-2 junior epidemiologist: $90-$130K. Year 3-5 Senior Epidemiologist: $130-$170K. Year 5-8 Senior/Principal Epidemiologist with regulatory-submission ownership: $160-$220K. Year 8-12 Associate Director, Epidemiology: $190-$260K. Year 12-15 Director, Epidemiology + RWE: $230-$320K. Year 15-20 Senior Director / Executive Director: $280-$420K. Year 20+ VP, Epidemiology: $350-$550K base + equity at biotech, $300-$450K base at large pharma. The trajectory bends fastest at year 5-8 when regulatory-submission ownership compounds, and again at year 12-15 when therapeutic-area-leadership compounds.

See Also

• The Pharm's career-pivot growth track — the career-stage architecture for academic-to-industry epidemiologists
• Public Health Resume Non-Academic: The 6 Employer Sub-Lanes — the broad public-health-vertical companion (this post narrows to epi)
• Epic Analyst Resume Non-IT Background — the adjacent healthcare-tech-data-pivot framework (Epic data exposure intersects with public-health-tech)
• Clinical Informatics Nurse Resume: The Bridging-Work Pattern — adjacent pivot framework for academic-to-tech transitions
• Why This Pivot: The Interview-Story Framework — the universal pivot-story framework that applies to epi career transitions